The transcription factor c-Myb is required for modulation of progenitor cells in several tissues, including skeletal muscle and its upregulation is observed in many human malignancies. Rhabdomyosarcomas (RMS) are a heterogeneous group of mesodermal tumors with features of developing skeletal muscle. Several miRNAs are downregulated in RMS, including miR-150, a negative regulator of c-Myb expression. Using the C2C12 myoblast cell line, a cellular model of skeletal muscle differentiation, we showed that miR-150 controls c-Myb expression mainly at the level of translation. We hypothesized that a similar mechanism of c-Myb regulation operates in RMS tumors. We examined expression of c-Myb by immunohistochemistry and revealed c-Myb positivity in alveolar and embryonal tumors, the two most common subgroups of RMS. Furthermore, we showed direct correlation between c-Myb production and myogenin expression. Interestingly, high myogenin levels indicate poor prognosis in RMS patients. c-Myb could, therefore, contribute to the tumor phenotype by executing its inhibitory role in skeletal muscle differentiation. We also showed that c-Myb protein is abundant in migratory C2C12 myoblasts and its ectopic expression potentiates cell motility. In summary, our results implicate that metastatic properties of some RMS subtypes might be linked to c-Myb function.

Laboratory of Cell Differentiation Institute of Molecular Genetics of the ASCR v v i Prague Czech Republic

Laboratory of Genomics and Bioinformatics Institute of Molecular Genetics of the ASCR v v i Prague Czech Republic

Laboratory of Transgenic Models of Diseases Institute of Molecular Genetics of the ASCR v v i Prague Czech Republic

The University Hospital Brno Brno Czech Republic

Zobrazit více v PubMed

Zhang Y., Jin H., Li L., Qin F. X. & Wen Z. cMyb regulates hematopoietic stem/progenitor cell mobilization during zebrafish hematopoiesis. Blood 118, 4093–4101, 10.1182/blood-2011-03-342501 (2011). PubMed DOI

Sandberg M. L. PubMed DOI

Malaterre J. PubMed DOI

Malaterre J. PubMed DOI PMC

Selvakumaran M., Liebermann D. A. & Hoffman-Liebermann B. Deregulated c-myb disrupts interleukin-6- or leukemia inhibitory factor-induced myeloid differentiation prior to c-myc: role in leukemogenesis. Mol Cell Biol 12, 2493–2500 (1992). PubMed PMC

Clarke M. F., Kukowska-Latallo J. F., Westin E., Smith M. & Prochownik E. V. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cell Biol 8, 884–892 (1988). PubMed PMC

Kolodziejska K. M. PubMed DOI

Kopecki Z. PubMed DOI

Kaspar P. PubMed DOI PMC

Xiao C. PubMed DOI

Grabher C. PubMed DOI PMC

Zhou Y. & Ness S. A. Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed) 16, 1109–1131 (2011). PubMed PMC

Ramsay R. G. & Gonda T. J. MYB function in normal and cancer cells. Nat Rev Cancer 8, 523–534, 10.1038/nrc2439 (2008). PubMed DOI

Ma Y. PubMed DOI

Machova Polakova K. PubMed DOI PMC

Sanghvi V. R. PubMed DOI PMC

Pappo A. S. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol 7, 361–366 (1995). PubMed

Fletcher C. D. M., World Health Organization. & International Agency for Research on Cancer.

Sebire N. J. & Malone M. Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56, 412–416 (2003). PubMed PMC

Altmannsberger M., Weber K., Droste R. & Osborn M. Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am J Pathol 118, 85–95 (1985). PubMed PMC

Tonin P. N., Scrable H., Shimada H. & Cavenee W. K. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 51, 5100–5106 (1991). PubMed

Parham D. M. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 14, 506–514, 10.1038/modpathol.3880339 (2001). PubMed DOI

Kumar S., Perlman E., Harris C. A., Raffeld M. & Tsokos M. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 13, 988–993, 10.1038/modpathol.3880179 (2000). PubMed DOI

Heerema-McKenney A. PubMed DOI

Ignatius M. S. PubMed DOI PMC

Li L., Sarver A. L., Alamgir S. & Subramanian S. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 92, 571–583, 10.1038/labinvest.2012.10 (2012). PubMed DOI

Davicioni E., Anderson J. R., Buckley J. D., Meyer W. H. & Triche T. J. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group. J Clin Oncol 28, 1240–1246, 10.1200/JCO.2008.21.1268 (2010). PubMed DOI PMC

Tanno B. PubMed DOI PMC

Knopfova L. PubMed DOI PMC

Quintana A. M., Liu F., O’Rourke J. P. & Ness S. A. Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer 11, 30, 10.1186/1471-2407-11-30 (2011). PubMed DOI PMC

Basu U. PubMed DOI PMC

Kaspar P. & Dvorak M. Involvement of phosphatidylserine externalization in the down-regulation of c-myb expression in differentiating C2C12 cells. Differentiation 76, 245–252, 10.1111/j.1432-0436.2007.00222.x (2008). PubMed DOI

Lei W., Liu F. & Ness S. A. Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1. Blood 105, 3855–3861, 10.1182/blood-2004-08-3342 (2005). PubMed DOI PMC

Nakata Y. PubMed DOI PMC

Sakamoto H. PubMed DOI

Lu J. PubMed DOI PMC

Furlong M. A., Mentzel T. & Fanburg-Smith J. C. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol 14, 595–603, 10.1038/modpathol.3880357 (2001). PubMed DOI

c-Myb regulates tumorigenic potential of embryonal rhabdomyosarcoma cells